HypertensionEDUHYPERNCT06704815
Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.
An observational study of Hypertension, run by Servier Affaires Médicales at 1 site in France.
Trial summary
The primary objective is to assess the change of systolic blood pressure from baseline after a 6-month follow up for hypertensive patients initiating Viacoram® plus an educational program (NGAYDAUTIEN) in comparison to hypertensive patients initiating other antihypertensive drugs (except single pill combination). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- Type of treatment
- Pill or oral medicine
- How many people
- 400 participants
- Where
- 1 siteFrance
- Study dates
- 31 Jan 2023to 12 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Male and female who have a diagnosis of grade 1 or 2 hypertension and who initiate a new antihypertensive treatment
Who may be able to join
- Aged of at least 18 years (without upper limit of age)
- Diagnosis of grade 1 or grade 2 hypertension
- Naïve of treatment:
- newly diagnosed hypertension and without treatment with antihypertensive effect for at least 3 months
- previously diagnosed but without treatment with antihypertensive effect for at least 3 months
- Patients follow-up within the scope of the current medical practice and in the same health centre during the 6-month period
Who cannot join
- Previously attended to the Ngay Dau Tien educational program for HBP management
- Plan to be hospitalized for other medical conditions during the next 6 months
- Plan to move/relocate during 6-month follow-up
- Have a severe disease (i.e. cirrhosis, end-stage renal disease …)
- Are unlikely to cooperate in the study
- Arm 1: patient having contra-indication to take Viacoram® according to SmPC
- Arm 2: patient showing interest in attending NDT educational program.
Trial locations and contacts
1 site in 1 country.
About this study
The primary objective is to assess the change of systolic blood pressure from baseline after a 6-month follow up for hypertensive patients initiating Viacoram® plus an educational program (NGAYDAUTIEN) in comparison to hypertensive patients initiating other antihypertensive drugs (except single pill combination).
- Conditions
- Hypertension
- Keywords
- observational, blood pressure, SBP, DBP, hypertension, HBP, HTA, Viacoram®, Perindopril arginine and Amlodipine, patient educational program
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Viacoram® plus educational program | naïve treatment hypertensive patients who will be initiated to Viacoram® plus an educational program | |
| other antihypertensive drugs (except Viacoram®) | naïve treatment hypertensive patients who will be initiated to any antihypertensive drug (except single pill combination) |
What is being measured
The primary outcome is the main question the study is designed to answer.
change of systolic blood pressure (measured in mmHg) from baseline after a 6-month follow up among the 2 arms
Measured: from baseline to 6-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Nov 2024
- Study start31 Jan 2023
- Primary completion12 Jun 2024
- Study completion12 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Servier Affaires Médicales
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06704815
- Sponsor's protocol ID
- DIM-05985-004
- Acronym
- EDUHYPER
- Status last verified
- Nov 2024
- First submitted
- 22 Nov 2024
- Last updated
- 26 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.
- ClinicalTrials.gov ID
- NCT06704815
- Acronym / sponsor ID
- EDUHYPER / DIM-05985-004
- Conditions
- Hypertension
- Keywords
- observational, blood pressure, SBP, DBP, hypertension, HBP, HTA, Viacoram®
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- Servier Affaires MédicalesIndustry (pharma, biotech, devices)
- Study start
- 31 Jan 2023 (actual)
- Primary completion
- 12 Jun 2024 (actual)
- Study completion
- 12 Jun 2024 (actual)
- First posted
- 26 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to assess the change of systolic blood pressure from baseline after a 6-month follow up for hypertensive patients initiating Viacoram® plus an educational program (NGAYDAUTIEN) in comparison to hypertensive patients initiating other antihypertensive drugs (except single pill combination).
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Viacoram® plus educational program | – | –naïve treatment hypertensive patients who will be initiated to Viacoram® plus an educational program |
| other antihypertensive drugs (except Viacoram®) | – | –naïve treatment hypertensive patients who will be initiated to any antihypertensive drug (except single pill combination) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Male and female who have a diagnosis of grade 1 or 2 hypertension and who initiate a new antihypertensive treatment
Key inclusion criteria (6 listed)
- Aged of at least 18 years (without upper limit of age)
- Diagnosis of grade 1 or grade 2 hypertension
- Naïve of treatment:
- Patients follow-up within the scope of the current medical practice and in the same health centre during the 6-month period
Key exclusion criteria (7 listed)
- Previously attended to the Ngay Dau Tien educational program for HBP management
- Plan to be hospitalized for other medical conditions during the next 6 months
- Plan to move/relocate during 6-month follow-up
- Have a severe disease (i.e. cirrhosis, end-stage renal disease …)
- Are unlikely to cooperate in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
change of systolic blood pressure (measured in mmHg) from baseline after a 6-month follow up among the 2 arms
Time frame: from baseline to 6-month follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2024.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Enrolling by invitationObservational study
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Acute Kidney Injury, Fluid Overload
RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Diabetes Mellitus, Type 2, Hypertension
RecruitingPhase 4
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Hypertension, Hypercortisolemia
RecruitingPhase 2
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension
RecruitingPhase 2
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension, run by Servier Affaires Médicales at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change of systolic blood pressure (measured in mmHg) from baseline after a 6-month follow up among the 2 arms (time frame: from baseline to 6-month follow-up). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2024.